Table 3 Treatment
Nref | Age (yrs) | Sex (M/F) | Medication received before bone marrow fibrosis | Immunomodulatory therapy for bone marrow fibrosis | Response |
|---|---|---|---|---|---|
1 (Sarkar et al.2009) | 45 | M | Prednisolone 60 mg/d | Improved | |
2 (Sacre et al.2009) | 44 | F | Prednisone, hydroxychloroquine | Prednisone 1 mg/kg/d, IVIg | Improved |
3 (Pillai et al.2009) | 40 | F | IV methylprednisolone 500 mg/d, prednisone | Improved | |
4 (Aziz et al.2004) | 22 | F | Prednisone 1 mg/kg/d | Improved | |
5 (Kiss et al.2000) | 18 | F | Prednisone, azathioprine discontinued 6 months prior | IV methylprednisolone 1 g/d ×3, prednisone 2 mg/kg/d, cyclosporine 3 mg/kg, azathioprine | Relapsed, secondary improvement |
6 (Durupt et al.2000) | 29 | F | Prednisone 2 mg/kg/d | Improved | |
7 (Vora et al.1998) | 22 | F | Prednisone, azathioprine initiated 2 weeks prior | Azathioprine discontinuation, 6 plasma exchanges, IV methylprednisolone 1 g pulses | Improved |
54 | F | Prednisone 80 mg/d, IVIg 400 mg/kg/d ×5 | Improved | ||
9 (Agarwal et al.1995) | 12 | F | Prednisone 2 mg/kg/d | Improved | |
10 (Ramakrishna et al.1995) | 18 | F | Prednisolone 75 mg/d, IVIg, splenectomy, danazol, colchicine, vincristine | Relapsed, secondary improvement | |
11 (Paquette et al.1994) | 68 | M | Prednisone 20 mg/d | Not improved | |
12 (Paquette et al.1994) | 27 | F | Prednisone 60 mg/d | Improved | |
13 (Paquette et al.1994) | 23 | F | Prednisone 50 mg/d | Improved | |
14 (Paquette et al.1994) | 56 | F | Prednisone | Prednisone | Not improved |
15 (Paquette et al.1994) | 18 | F | Prednisone 80 mg/d | Improved | |
16 (Paquette et al.1994) | 70 | F | Prednisone | Deceased | |
17 (Paquette et al.1994) | 62 | F | Deceased | ||
18 (Paquette et al.1994) | 69 | F | Prednisone, splenectomy | Relapsed, secondary improvement | |
19 (Hirose et al.1993) | 54 | F | IV methylprednisolone 1 g/d ×3, prednisone 60 mg/d | Improved | |
20 (Borba et al.1993) | 39 | F | Prednisone, hydroxychloroquine | Methylprednisolone, prednisone, plasma exchanges, cyclophosphamide | Relapsed, secondary Improvement |
21 (Foley-Nolan et al.1992) | 20 | F | Prednisolone 40 mg/d, azathioprine 50 mg/d | Relapsed, secondary improvement | |
22 (Inoue et al.1992) | 24 | F | Prednisolone 1,2 mg/kg/d, IV methylprednisolone 1 g/d ×3 | Improved | |
23 (Matsouka et al.1989) | 60 | F | Hydrocortisone 1 g/d | Deceased | |
24 (el Mouzan et al.1988) | 13 | F | Prednisolone 30 mg/d | Improved | |
25 (Kaelin and Spivak1986) | 27 | F | Prednisone, salicyclate | IV methylprednisolone 100 mg/d ×6, prednisone 50 mg/d | Improved |
26 (Nanji and Jetha1984) | 28 | M | Prednisone | Deceased | |
27 (Daly and Scott1983) | 16 | F | NSAID including oxyphenbutazone | Prednisolone 30 mg/d | Improved |
Present | 29 | F | Olanzapine | IV methylprednisolone 500 mg/d ×3, prednisone 1 mg/kg and hydroxychloroquine, IVIg 30 g/d ×4 | Improved |